治疗阿尔茨海默病的淋巴治疗药物:是时候移动针了
ArunSundar MohanaSundaram1, Mohammad Mofatteh2, Ghulam Md Ashraf3
1School of Pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamilnadu 600119, India.
Ageing research reviews
|September 2, 2024
概括
阿尔茨海默病的治疗面临着挑战. 用新的"淋巴疗法"准淋巴系统可能提供一种新的策略来清除粉样β和蛋白,从而有可能改善结果.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,构成了全球重大健康挑战.
- 目前针对阿尔茨海默氏症的疾病修饰疗法,例如向粉样蛋白-β (Aβ) 的单克隆抗体,已显示出可争议的有效性,并带来了与粉样蛋白相关的成像异常和中风等安全问题.
- 现有的治疗方法突显出需要新的治疗策略,而不仅仅是粉样β去除.
研究的目的:
- 探索向淋巴系统以治疗阿尔茨海默病的潜力.
- 提出一种新的治疗范式,重点是通过淋巴管路径增强Aβ和tau蛋白质的清除.
- 倡导药物发现工作,以促进淋巴清除的药物为中心,称为"淋巴疗法".
主要方法:
- 审查当前的阿尔茨海默病治疗方法及其局限性.
- 分析水素-4在Aβ和tau蛋白的神经周血管清除中的作用.
- 开发促进淋巴清除药物的概念框架.
主要成果:
- 目前针对β-粉样蛋白的向疗法的疗效和安全性仍在讨论中.
- 通过aquaporin-4介导的淋巴管道是神经退行性疾病清除的有希望的目标.
- 淋巴管疗法为缓解AD进展提供了一个潜在的可行的策略.
结论:
- 对于阿尔茨海默病,迫切需要新的治疗策略.
- 向淋巴系统为增强Aβ和tau等有毒蛋白质的清除提供了一个有希望的途径.
- 淋巴治疗药物的开发可以在控制阿尔茨海默病的进展和改善患者的治疗结果方面取得重大进展.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454


